MOST is a phase II trial conducted in adult patients with an advanced solid tumor in progression after at least 1 prior treatment regimen. The study aims to assess whether a 12-week treatment with a targeted therapy selected based on the alteration(s) detected in the tumor is sufficient to stabilize the disease compared with a longer treatment, for all patients presenting this alteration, regardless of the primary disease site or cancer type. All the targeted therapies administered in MOST study already obtained a marketing authorization (MA) but will be evaluated in indications other than those defined in their MA.